Cholangitis

Gilead Sciences‘ Livdelzi (seladelpar) effectively reduces blood levels of alkaline phosphatase (ALP), a key marker of liver damage, in most people with primary…

Assembly Biosciences plans to develop its investigational oral treatment, ABI-6250, for people with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC). The…

People with primary biliary cholangitis (PBC) who experience itching (pruritus) use more healthcare resources and have significantly higher medical costs than those without this…

Low blood levels of vitamin B6 — found in certain foods and essential for metabolism and immune function in the body — can increase the…

Twice-daily treatment with volixibat, Mirum Pharmaceuticals’ oral investigational therapy for primary sclerosing cholangitis (PSC) significantly outperformed a placebo in reducing moderate to severe…

Adults with primary biliary cholangitis (PBC) who have less elevated blood levels of the liver enzyme alkaline phosphatase (ALP), a marker of liver damage, at…

Scheduled MRI scans one to three years after a liver transplant may detect signs of returning primary sclerosing cholangitis (PSC) earlier than standard blood-based liver…

April 19 marks World Liver Day, a global effort to raise awareness about liver health and the growing burden of liver disease. This year’s…

Long-term, off-label treatment with fenofibrate significantly reduces liver damage markers and improves prognostic scores in primary biliary cholangitis (PBC) patients who do not respond…

April is officially recognized in the U.S. as National Donate Life Month, an opportunity to highlight the extraordinary impact of organ donation, and the…